Sylvén C - Search Results

1

ANP and BNP but not VEGF are regionally overexpressed in ischemic human myocardium.

Rück A, Gustafsson T, Norrbom J, Nowak J, Källner G, Söderberg M, Sylvén C, Drvota V. Rück A, et al. Among authors: sylven c. Biochem Biophys Res Commun. 2004 Sep 10;322(1):287-91. doi: 10.1016/j.bbrc.2004.07.114. Biochem Biophys Res Commun. 2004. PMID: 15313204

2

[There is a crunch in assessment of non-pharmacological therapy. Controlled trials necessary in refractory angina pectoris].

Rück A, Sylvén C. Rück A, et al. Among authors: sylven c. Lakartidningen. 2006 Jun 14-27;103(24-25):1918-9. Lakartidningen. 2006. PMID: 16838575 Swedish. No abstract available.

3

Therapeutic angiogenesis gains a leg to stand on.

Rück A, Sylvén C. Rück A, et al. Among authors: sylven c. Mol Ther. 2008 May;16(5):808-10. doi: 10.1038/mt.2008.65. Mol Ther. 2008. PMID: 18432271 Free article. No abstract available.

4

Refractory angina pectoris carries a favourable prognosis: a three-year follow-up of 150 patients.

Rück A, Sylvén C; EUROINJECT ONE study group. Rück A, et al. Among authors: sylven c. Scand Cardiovasc J. 2008 Oct;42(5):291-4. doi: 10.1080/14017430802084997. Scand Cardiovasc J. 2008. PMID: 18609054 Free article.

5

Rosuvastatin inhibits TIMP-2 and promotes myocardial angiogenesis.

Siddiqui AJ, Gustafsson T, Sylven C, Crisby M. Siddiqui AJ, et al. Among authors: sylven c. Pharmacology. 2014;93(3-4):178-84. doi: 10.1159/000360860. Epub 2014 May 17. Pharmacology. 2014. PMID: 24854110

6

Characterization of AT-1 cardiomyocytes as a model for studies of T3 effects on cardiac cells.

Shahrara S, Drvota V, Blange I, Törmä H, Sylvén C. Shahrara S, et al. Among authors: sylven c. Biochem Biophys Res Commun. 1997 Aug 18;237(2):303-6. doi: 10.1006/bbrc.1997.7139. Biochem Biophys Res Commun. 1997. PMID: 9268705

7

Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris.

Sylvén C, Sarkar N, Rück A, Drvota V, Hassan SY, Lind B, Nygren A, Källner Q, Blomberg P, van der Linden J, Lindblom D, Brodin LA, Islam KB. Sylvén C, et al. Coron Artery Dis. 2001 May;12(3):239-43. doi: 10.1097/00019501-200105000-00010. Coron Artery Dis. 2001. PMID: 11352080

8

Protein and angiogenic dose-response expression of phVEGF-A(165) gene in rat myocardium.

Sylvén C, Sarkar N, Wärdell E, Jämsä A, Drvota V, Blomberg P, Bin Islam K. Sylvén C, et al. J Thromb Thrombolysis. 2001 Oct;12(2):151-6. doi: 10.1023/a:1012971421128. J Thromb Thrombolysis. 2001. PMID: 11729366

9

[Evident placebo effect in refractory angina pectoris. Do refer to the placebo-controlled study at the Huddinge hospital!].

Rück A, Drvota V, Sylvén C. Rück A, et al. Among authors: sylven c. Lakartidningen. 2001 Dec 12;98(50):5794-5. Lakartidningen. 2001. PMID: 11789107 Swedish. No abstract available.

10

Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease--12-month follow-up: angiogenic gene therapy.

Sarkar N, Rück A, Källner G, Y-Hassan S, Blomberg P, Islam KB, van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin LA, Drvota V, Sylvén C. Sarkar N, et al. Among authors: sylven c. J Intern Med. 2001 Nov;250(5):373-81. doi: 10.1046/j.1365-2796.2001.00905.x. J Intern Med. 2001. PMID: 11887971 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

292 results

Search Page

Filters